Table 2.
Adverse events reported in patients treated with lenvatinib
| Low risk n | Medium risk n | High risk n | P value | |
|---|---|---|---|---|
| HSFR | ||||
| Yes | 43 (33.6) | 32 (19.7) | 20 (17.5) | 0.0046 |
| No | 85 | 130 | 94 | |
| Diarrhea | ||||
| Yes | 37 | 47 | 21 | 0.0939 |
| No | 91 | 115 | 93 | |
| Hypertension | ||||
| Yes | 66 (51.5) | 60 (37.0) | 27 (23.6) | <0.0001 |
| No | 62 | 102 | 87 | |
| Fatigue | ||||
| Yes | 49 | 68 | 39 | 0.4251 |
| No | 79 | 94 | 75 | |
| Decreased appetite | ||||
| Yes | 45 | 68 | 40 | 0.3798 |
| No | 83 | 94 | 74 | |
| Proteinuria | ||||
| Yes | 51 (39.8) | 57 (35.2) | 25 (21.9) | 0.0091 |
| No | 77 | 105 | 89 | |
| Hypothyroidism | ||||
| Yes | 56 | 64 | 38 | 0.2509 |
| No | 72 | 98 | 76 | |
| Other toxicity | ||||
| Yes | 79 | 95 | 55 | 0.0871 |
| No | 49 | 67 | 59 |
The positive results were in bold.
HSFR, hand-foot skin reaction.